Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial
| Autor: | C.M. Østby, Katrine Rolid, Lars Gullestad, Einar Gude, Kaspar Broch, Arne K. Andreassen, Kristine V. Brautaset Englund |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Adolescent medicine.medical_treatment 030204 cardiovascular system & hematology Disaccharides Placebo Ferric Compounds law.invention Young Adult 03 medical and health sciences Oxygen Consumption 0302 clinical medicine Double-Blind Method Randomized controlled trial law medicine Clinical endpoint Humans 030212 general & internal medicine Infusions Intravenous Aged Aged 80 and over Heart Failure Heart transplantation Transplantation biology Transferrin saturation business.industry Iron Deficiencies Iron deficiency Middle Aged medicine.disease Transplant Recipients Ferritin Anesthesia Quality of Life biology.protein Heart Transplantation Female Surgery Cardiology and Cardiovascular Medicine business |
| ISSN: | 1053-2498 |
| Popis: | Aims Heart transplant recipients have reduced exercise capacity despite preserved graft function. The IronIC trial was designed to test the hypothesis that intravenous iron therapy would improve peak oxygen consumption in these patients. Methods and results This randomized, placebo-controlled, double-blind trial was performed at our national center for heart transplantation. One hundred and 2 heart transplant recipients with a serum ferritin 100 g/liter were enrolled ≥1 year after transplantation. A cardiopulmonary exercise test was performed before administration of the study drug and at 6 months follow-up. The primary endpoint was peak oxygen consumption. Key secondary outcomes included iron status, handgrip strength, quality of life, and safety. Fifty-two patients were randomized to receive ferric derisomaltose 20 mg/kg, and 50 to placebo. The between-group difference in baseline-adjusted peak oxygen consumption was 0.3 ml/kg/min (95% confidence interval -0.9 to 1.4, p = 0.66). In patients with a baseline ferritin |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|